RESUMO
AIM: To assess the prevalence of mild gastrointestinal disorders in milk-fed infants in paediatric practice, and to evaluate the effectiveness and satisfaction with dietetic treatment. METHODS: A cross-sectional epidemiological study was first carried out. A total of 285 paediatricians included 3487 children seen during a period of one week. In a second phase an observational, prospective and multicentre study was conducted and 2069 milk-fed infants with mild gastrointestinal disorders (colic, constipation, regurgitation and diarrhoea) were included. There was a baseline visit (start of treatment) and a final visit four weeks later. The effectiveness of the various Novalac formulas, as well as the satisfaction of the parents/tutors and paediatricians with the dietetic treatment were assessed at the final visit. RESULTS: The prevalence of mild gastrointestinal disorders was 27.8% of all paediatrician consultations (9.2%, 7.8%, 6.1% and 4.6% in relation to colic, constipation, regurgitation and diarrhoea, respectively). The several Novalac adapted milk formulas resolved 88.4% of the mild gastrointestinal disorders. Depending on the type of disorder, differences in response rate were observed. The highest effectiveness was recorded with respect to diarrhoea (92.6%), followed by constipation (91.6%), colic (87.6%) and regurgitation (81%). Overall, 91% of the paediatricians and 88.8% of the parents/tutors were satisfied or very satisfied with the Novalac adapted milk formulas. CONCLUSION: Mild gastrointestinal disorders show a high prevalence in paediatric practice. The Novalac adapted milk formulas have been shown to be effective in treating mild gastrointestinal disorders in milk-fed infants in the context of routine clinical practice.
Assuntos
Gastroenteropatias/dietoterapia , Gastroenteropatias/epidemiologia , Fórmulas Infantis/administração & dosagem , Leite , Animais , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Satisfação do Paciente , PrevalênciaRESUMO
A multicentric, double-blind and randomized clinical study was conducted on a total of 54 patients with hyperlipidemias type IIa, IIb and IV in order to compare the effectivity and tolerance of two hyperlipemiant drugs: Binifibrate and Gemfibrozil. The treatment had a length of six months, performing clinical and analytical controls at: baseline, 1 month, 2 months, 4 months and 6 months. Both drugs showed a very good tolerance and the following results were obtained: Total cholesterol: Binifibrate -21.9%, Gemfibrozil -20.5%; Triglycerides: Binifibrate -48.6%, Gemfibrozil -43.27%; HDL: Binifibrate +18.2%, Gemfibrozil -12.8%; LDL: Binifibrate -24.3%, Gemfibrozil -22.8% VLDL: Binifibrate -48%, Gemfibrozil -43.2%; Apo A: Binifibrate +133.5%, Gemfibrozil +108.1%; Apo B: Binifibrate -59.7%, Gemfibrozil -46%. Both treatment were very effective, although the greater increase produced by Binifibrate on Chol-HDL, with a statistically significant difference versus the increase produced by Gemfibrozil, must be highlighted.